61995-20-8

Basic information

• Product Name: 1-N-CBZ-3-PIPERIDONE
• Synonyms: 3-OXO-PIPERIDINE-1-CARBOXYLIC ACID BENZYL ESTER;1-N-CBZ-3-PIPERIDONE;1-CBZ-3-PIPERIDINONE;1-CBZ-3-PIPERIDONE;BENZYL 3-OXOPIPERIDINE-1-CARBOXYLATE;N-Cbz-3-Piperidone;1-Benzyloxycarbonyl-3-piperidone, 97+%;1-Piperidinecarboxylic acid, 3-oxo-, phenylmethyl ester
• CAS NO: 61995-20-8
• Molecular Formula: C₁₃H₁₅NO₃
• Molecular Weight: 233.26
• Product Categories: pharmacetical;Piperidine
• Mol File: 61995-20-8.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 384.1 °C at 760 mmHg
• Flash Point: 186.1 °C
• Appearance: /Liquid
• Density: 1.212
• Vapor Pressure: 4.18E-06mmHg at 25°C
• Refractive Index: 1.56
• Storage Temp.: 2-8°C
• PKA: -1.76±0.20(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 1-N-CBZ-3-PIPERIDONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-N-CBZ-3-PIPERIDONE(61995-20-8)
• EPA Substance Registry System: 1-N-CBZ-3-PIPERIDONE(61995-20-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36/37/38
• Safety Statements: 23-26-37-60
• Hazardous Substances Data: 61995-20-8(Hazardous Substances Data)

Usage

Uses

1-Benzyloxycarbonyl-3-piperidone finds its application in the synthesis and pharmacological evaluation of some 6-substituted 7-methyl-1,4-dioxa-7-azaspiro[4.5]decanes as potential dopamine agonists.

InChI:InChI=1/C13H15NO3/c15-12-7-4-8-14(9-12)13(16)17-10-11-5-2-1-3-6-11/h1-3,5-6H,4,7-10H2

Upstream product

• 40114-49-6 1-benzyl-3-piperidone 
• 501-53-1 benzyl chloroformate 
• 6859-99-0 3-hydroxypiperazine 
• 61644-00-6 piperidin-3-one hydrochloride 
• 50717-82-3 piperidin-3-one 
• 5105-78-2 4-(benzyloxycarbonylamino)butyric acid 
• 95798-22-4 3-hydroxy-piperidine-1-carboxylic acid benzyl ester 
• 50606-58-1 N-benzyl-3-piperidinone hydrochloride 

Downstream Products

• 149108-73-6 Benzyl 1,2,3,4-tetrahydro-5-<(trifluoromethyl)sulfonyloxy>-pyridine-1-carboxylate 
• 138163-15-2 3-methylenepiperidine-1-carboxylic acid benzyl ester 
• 227959-50-4 3-(ethoxy-methyl-phosphinoyl)-3-hydroxy-piperidine-1-carboxylic acid benzyl ester 
• 227959-44-6 3-(diethoxymethyl-ethoxy-phosphinoyl)-3-hydroxy-piperidine-1-carboxylic acid benzyl ester 
• 199102-72-2 2-amino-7-benzyloxycarbonyl-3-(3,4-dimethoxybenzoyl)-4,5,6,7-tetrahydrothieno[2,3-b]pyridine 
• 528594-63-0 benzyl 1,4-dioxa-7-azaspiro[4,5]decane-7-carboxylate 
• 199102-09-5 ethyl 2-(diethylaminomethyl)-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydrothieno[2,3-b:5,4-b']dipyridine-3-carboxylate 
• 199102-76-6 7-chloromethyl-5-(3,4-dimethoxy-phenyl)-3,4-dihydro-2H-thieno[2,3-b;5,4-b']dipyridine-1,6-dicarboxylic acid 1-benzyl ester 6-ethyl ester 
• 199102-06-2 ethyl 8-benzyloxycarbonyl-2-diethylaminomethyl-4-(3,4-dimethoxyphenyl)-5,6,7,8-tetrahydrothieno[2,3-b:5,4-b']dipyridine-3-carboxylate 
• 227959-52-6 3-(ethoxy-methyl-phosphinoyl)-piperidine-1-carboxylic acid benzyl ester 
• 227959-51-5 oxalic acid 1-benzyloxycarbonyl-3-(ethoxy-methyl-phosphinoyl)-piperidin-3-yl ester methyl ester 
• 227959-48-0 3-(diethoxymethyl-ethoxy-phosphinoyl)-piperidine-1-carboxylic acid benzyl ester 
• 227959-46-8 oxalic acid 1-benzyloxycarbonyl-3-(diethoxymethyl-ethoxy-phosphinoyl)-piperidin-3-yl ester methyl ester 
• 276872-92-5 N-(benzyloxycarbonyl)-2-phenylmethyl-3-piperidone 

Relevant articles and documents

AROMATIC COMPOUND

Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

BRUTON'S TYROSINE KINASE INHIBITORS

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

Piperididinyl and N-amidinopiperidinyl derivatives

This invention is directed to a compound of formula I which is useful for inhibiting the activity of Factor Xa, by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds